| Document |
Document Title |
|
WO/2024/046409A1 |
The present invention relates to a heterocyclic compound, a preparation method therefor, and a pharmaceutical use thereof. Specifically, the present invention relates to a heterocyclic compound as shown in general formula (I), a preparat...
|
|
WO/2023/224020A1 |
Provided is a compound represented by formula (1). (The symbols in formula (1) are as defined in the specification.) Also provided are an organic electroluminescent element that contains the compound and an electronic device that include...
|
|
WO/2022/256702A1 |
Compounds of formula I and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and m...
|
|
WO/2022/006457A1 |
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
|
|
WO/2022/006456A1 |
The present application provides tricyclic pyridone compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
|
|
WO/2021/252644A1 |
The disclosure provides compounds of formula II with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provid...
|
|
WO/2021/111351A1 |
The present invention relates to novel heterocyclic compounds of general formula (I) their tautomers, stereoisomers, enantiomers, pharmaceutically acceptable salts and pharmaceutical composition. The compounds of general formula (I) belo...
|
|
WO/2021/094269A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
|
WO/2021/066873A1 |
The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a ...
|
|
WO/2020/082656A1 |
The prevent invention provides a macromolecule Thermally Activated Delayed Fluorescence (TADF) material, and further provides a TADF monomolecular white light material, which is synthesized from raw materials of first groups and second g...
|
|
WO/2019/234075A1 |
The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)ben
zimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea, atopic dermatitis, psor...
|
|
WO/2019/084271A1 |
The disclosure relates to compounds that are, e.g., PAP Associated Domain Containing 5 (PAPD5) inhibitors and methods of use thereof.
|
|
WO/2018/078657A1 |
The present invention discloses a simple, economic, consistent, commercially viable and industrially applicable process for preparation of Glipizide in high yield and highly pure Glipizide having purity more than 95%, preferably more tha...
|
|
WO/2016/201354A1 |
Described are compositions and methods for treating cancer. Some methods comprise the administration of an effective amount of at least one inhibitor of tryptophan 2, 3-dioxygenase (TDO) and/or indoleamine 2, 3-dioxygenase (IDO), optiona...
|
|
WO/2015/111943A1 |
The present invention relates to an organic compound, and an organic electroluminescent device containing the same. The luminescence efficiency, driving voltage, lifetime and the like of an organic electroluminescent device can be improv...
|
|
WO/2013/072896A1 |
The present invention is related to variants of mycolactones of formula (I), processes for the preparation thereof, pharmaceutical compositions thereof and their use in modulating inflammation, immunity and pain. Y-O-W (I), wherein Y and...
|
|
WO/2012/174564A1 |
Methods of preparing hetero ionic complexes, and ionic liquids from bisulfate salts of heteroatomic compounds using dialkylcarbonates as a primary quaternizing reactant are disclosed. Also disclosed are methods of making electrochemical ...
|
|
WO/2010/063069A1 |
The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compoun...
|
|
WO/2009/089482A1 |
Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R1 is H or optionally substituted alkyl; R2, R3, R4 are each independently selecte...
|
|
WO/2008/122115A1 |
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula compounds of the Formula (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable ...
|
|
WO/2007/138307A2 |
A sulfur-containing acid removal process for deacidifying a crude oil and/or crude oil distillate containing sulfur-containing acids comprising the steps of: (a) contacting the crude oil and/or crude oil distillate containing sulfur-cont...
|
|
WO/2007/134958A1 |
There are presented compounds of the formula (I) wherein R1, R2, R3 and R4 are as defined in the description and claims, or a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the...
|
|
WO/2007/108742A1 |
The present invention relates to new compounds of formula I, or salts, solvates or solvated salts thereof, wherein Q, R1, R2, R3, R4 and n are defined as in claim 1, processes for their preparation and to new intermediates used in the pr...
|
|
WO/2007/087684A1 |
The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.
|
|
WO/2006/073967A1 |
Compounds useful as prodrugs of potassium channel inhibitor compounds, in particular as prodrugs of Kv1.5 channel inhibitors.
|
|
WO/2005/116020A1 |
Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them...
|
|
WO/2005/100370A1 |
The present invention refers to new compounds derived from artesunate salts with quinolines represented by the general formula (I) where X is represented by the general formula (II) and Y is represented by the general formula (III) depen...
|
|
WO/2005/075422A1 |
The invention relates to a process for the manufacture of an 1,2,4-triazol-1-yl compound of the formula [A], or a salt thereof, wherein each of R3 and R4 is hydrogen or lower alkyl, said process comprising reacting a hydrazine compound o...
|
|
WO/2005/070896A1 |
The invention relates to a method for producing ionic liquids consisting first in reacting an ionic liquid with an alkylate, a hydrogencarbonate, a carbonate, a carboxylate or a hydroxide and, afterwards in neutralising with an acid. The...
|
|
WO/2005/070923A1 |
A crystalline polymorph of a bislulfate salt of a thrombin receptor antagonist compound, which exhibits a powder x-ray diffraction profile substantially the same as that shown in FIG. 1, or which exhibits a differential scanning calorimt...
|
|
WO/2005/068404A1 |
The invention relates to a method for the distillation of ionic liquids. According to said method, in one step the pressure is set to a value below the ambient pressure and in a subsequent step, the ionic liquid is heated to a temperatur...
|
|
WO/2005/058916A2 |
The present invention relates to organometallic transition metal compounds of formula (I) where M1, X, n, Z, R1-R8 and A are as defined in the claims, biscyclopentadienyl ligand systems having such a substitution pattern, catalyst system...
|
|
WO/2005/046688A2 |
A method of treating a therapeutic condition comprising administering to a mammal in need of such treatment an effective amount of at least one compound of the formulas (I) and (II) or a pharmaceutically acceptable isomer, salt, solvate ...
|
|
WO/2005/040121A2 |
The present invention relates to compounds of formula (I), that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.
|
|
WO/2005/037954A1 |
Disclosed is a compound represented by formula 1: wherein each of A, X, Y, Y’, and Y’’ has the same meaning as described herein. When used in an organic light emitting device, the compound represented by formula 1 has at least one ...
|
|
WO/2005/030712A2 |
A series of compounds represented by the structural formulas and pharmaceutically acceptable isomers, salts, solvates and polymorphs thereof are disclosed. Also disclosed are pharmaceutical compositions containing said compounds and thei...
|
|
WO/2005/023235A1 |
The invention aims at providing novel low-molecular compounds which have G-CSF-like activities and can substitute for G-CSF preparations. The invention relates to G-CSF-like agonists containing as the active ingredient benzyl alcohol der...
|
|
WO/2005/019183A1 |
Disclosed is a method for producing purified 1,3-substituted imidazolium salts of general formula (I) by reacting a 1,3-substituted imidazolium salt of general formula (II) with a strong base at a temperature ranging between 20 and 250 Â...
|
|
WO/2005/016890A1 |
Compounds of Formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
|
|
WO/2005/014583A1 |
An azole derivative of formula (I) having a fluorovinyl moiety or a pharmaceutically acceptable salt thereof is superior to the conventional antifungal drugs in antifungal activity against a wide spectrum of pathogenic fungi, and has adv...
|
|
WO/2004/093828A2 |
Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, ...
|
|
WO/2004/089914A1 |
The invention relates to benzenesulphonamide derivatives of formula (I), methods and intermediate products for production thereof and use of said compounds, or means comprising said compounds for the control of undesired plants and for t...
|
|
WO/2004/084901A1 |
This invention generally relates to methods for treating or preventing a condition responsive to JNK inhibition, such as a metabolic condition, comprising administering to a patient in need thereof an effective amount of an Anilinopyrimi...
|
|
WO/2004/083208A1 |
The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesi...
|
|
WO/2004/080973A1 |
Compounds having the formula (I) (I), are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
|
|
WO/2004/080974A1 |
Disclosed is an ionic liquid purification method for preparing high purity ionic liquids which can be used as solvents for organic, inorganic and biochemical reactions or as electrolytic solutions of storage batteries, secondary batterie...
|
|
WO/2004/072031A2 |
Compounds of Formula (I): or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.
|
|
WO/2004/071390A2 |
The present invention is related to piperazine -2-carboxamide derivatives of formula (I) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. Wherein A, X...
|
|
WO/2004/069823A1 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...
|
|
WO/2004/069797A1 |
The invention relates to novel heteroaryl-substituted acetone derivatives, which inhibit the enzyme phospholipase A2, to pharmaceutical agents that contain said compounds and to a method for producing said compounds.
|
